Table 2.
Trials Examining Arginine-Supplementation in Cancer Patients
| Trial | Status | Subjects (enrollment) | Phase | Arginine Dose | Endpoint / Findings |
|---|---|---|---|---|---|
| NCT02017249 | Results Pending | Glioblastoma Multiforme (n=1) |
1 | 24.15g TID x 14 days | Change in Immune Function Labs/Testing |
| NCT00006340 | Ongoing | EBV(+) Cancer or Lymphoproliferative disorders (n=20) |
1 | Escalating Arginine dose with ganciclovir therapy | Safety and Toxicity |
| NCT00917826 | Terminated | EBV(+) Lymphoid Malignancies (n=1) |
1 | - | - |
Abbreviations: EBV, Epstein Barr Virus; TID, 3 times daily.